| Nov 5 |
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
|
| Oct 16 |
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide
|
| Oct 16 |
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
|
| Oct 7 |
Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
|
| Sep 17 |
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
|
| Aug 20 |
BLRX: On Track for 60% Formulary Placement
|
| Aug 15 |
BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript
|
| Aug 15 |
BioLineRx GAAP EPS of $0.00, revenue of $5.39M
|
| Aug 15 |
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
|
| Aug 14 |
biolinerx Q2 Earnings Preview
|
